drugset

drugset / Trial / NCT00267488

Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer

NCT00267488 ↗

Phase 2 Completed 70 enrolled GlaxoSmithKline

RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out if Hycamtin given weekly is safe and effective for treating your endometrial cancer.

Timeline

Start: 2005-10
Primary completion: 2007-12
Completion: 2007-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Topotecan	Small molecule	—	Intravenous

Indications